Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Discontinuation of Anti-HER-2 Maintenance Treatment.
- Who it may be relevant to
- Registry conditions: HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
Overview
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Interventions
- Other Discontinuation of Anti-HER-2 Maintenance Treatment
Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
Primary outcome measures
- Feasibility of maintaining remission after discontinuing use of anti-HER-2 [Time frame: Up to 72 months]
Secondary outcome measures (3)
- Ability of re-attain remission after ctDNA+ status [Time frame: Up to 72 months]
- Duration of response (DOR) [Time frame: Up to 72 months]
- Diagnostic Accuracy of ctDNA Monitoring Assay to Identify Disease Progression [Time frame: Up to 72 months]
Eligibility criteria
Inclusion criteria
- Patients with a diagnosis of HER-2 positive metastatic (Stage IV) breast cancer.
- Patients in complete radiological remission (CRR), including a stable bone scan, as determined by computed tomography (CT), positron-emission tomography (PET), or PET-CT.
a. Patients with brain metastasis are allowed to participate as long as their disease has been treated and radiologically stable for at least 36 months.
- Patients must be on the same or current anti-HER-2 directed therapy for at least 36 months.
- Archived tumor biopsy available.
- Patients with no evidence of circulating tumor deoxyribonucleic acid (ctDNA) as determined by the Signatera assay.
- Patients willing to stop maintenance anti-HER-2 directed therapy with close monitoring.
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance score from 0 to 2.
- Patients ≥ 18 years of age.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
- Patients with uncontrolled metastatic disease.
- Patients whose disease has been controlled for less than 36 months on the same or current anti-HER-2 therapy.
- Patients who are currently receiving or have received treatment for a secondary cancer other than resected non-melanoma skin cancer lesions or in situ cancer within the past 24 months.
- Patients positive for ctDNA (which occurs when a patient's blood sample contains ≥2 target markers) with the Signatera assay.
- Use of investigational drugs ≤ 28 days prior to study enrollment and during the study.
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or that makes participation in the trial to be not in the best interest of the patient in the opinion of the Investigator.
- Patients with impaired decision-making capacity.
Patients who are found to be ctDNA+ at study entry will be recorded as a screen failure (Section 5.4). Their Signatera testing results will be provided to their treating physician to aid in clinical decision-making for disease management and treatment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
United States · 1 center
- University of Miami — Miami
Identifiers
NCT: NCT05959291 · 20221166